REG - Scancell Holdings - Share Option Exercise

Scancell HoldingsAnnouncement

16/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250716:nRSP1690Ra&default-theme=true

RNS Number : 1690R  Scancell Holdings Plc  16 July 2025

16 July 2025

 

Scancell Holdings plc

("Scancell" or the "Company")

Share Option Exercise

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapy
products for the treatment of multiple cancers, announces that is has received
notice from a former employee of the Company to exercise options over
1,000,000 ordinary shares of 0.1 pence each in the Company ("Ordinary Shares")
at an exercise price of 8.15 pence per share.

An application has been made to London Stock Exchange plc for the new
Ordinary Shares to be admitted to trading on AIM ("Admission").It is expected
that Admission will become effective and dealings commence at 8.00
a.m. on or around, 21 July 2025. The new Ordinary Shares will rank pari
passu with the existing ordinary shares of the Company.

Total Voting Rights

Following Admission, the total number of ordinary shares in issue will be
1,037,781,403. The Company does not hold any ordinary shares in treasury.
Therefore, the total number of ordinary shares with voting rights will be
1,037,781,403. This figure may be used by shareholders in the Company as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
share capital of the Company under the Financial Conduct Authority's
Disclosure and Transparency Rules.

 

 For more information please contact:

 Scancell Holdings plc                                   +44 (0) 20 3709 5700
 Phil L'Huillier, CEO
 Sath Nirmalananthan, CFO

 Panmure Liberum (Nominated Adviser and Joint Broker)    +44 (0) 20 7886 2500
 Emma Earl, Will Goode, Mark Rogers (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Joint Broker)                          +44 (0) 20 3705 9330

 David Wilson, Claes Spang

 Investor and media relations                            +44 (0) 20 7483 284853

 Mary-Ann Chang                                          MaryAnnChang@scancell.co.uk

Scancell (LSE:SCLP; www.scancell.co.uk (http://www.scancell.co.uk) ) is a
clinical stage biotechnology company developing targeted off-the-shelf
immunotherapies which enhance long-lasting tumour specific immunity for a
cancer-free future. Scancell's lead product, iSCIB1+ immunotherapy, has shown
strong promise, showing  clinically meaningful additional benefit when
combined with checkpoint therapies. The second immunotherapy, Modi-1, is being
investigated in a phase 2 study in a broad range of solid tumours. Scancell
also has an exciting early-stage pipeline of high affinity GlyMab® antibodies
targeting tumour specific glycans. Two GlyMab® antibodies are being developed
by Genmab under license from Scancell.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEGPUACMUPAGWA